Nomura Asset Management Co. Ltd. Sells 91,386 Shares of Boston Scientific Co. (NYSE:BSX)

Nomura Asset Management Co. Ltd. lowered its stake in Boston Scientific Co. (NYSE:BSX - Free Report) by 7.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,173,808 shares of the medical equipment provider's stock after selling 91,386 shares during the quarter. Nomura Asset Management Co. Ltd. owned about 0.08% of Boston Scientific worth $98,365,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. MML Investors Services LLC boosted its stake in Boston Scientific by 4.4% in the 3rd quarter. MML Investors Services LLC now owns 88,808 shares of the medical equipment provider's stock worth $7,442,000 after purchasing an additional 3,771 shares during the period. Dunhill Financial LLC grew its stake in shares of Boston Scientific by 86.4% during the 3rd quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider's stock worth $28,000 after acquiring an additional 152 shares in the last quarter. XTX Topco Ltd acquired a new stake in Boston Scientific in the 3rd quarter valued at $1,134,000. Zacks Investment Management increased its position in shares of Boston Scientific by 7.5% in the third quarter. Zacks Investment Management now owns 255,818 shares of the medical equipment provider's stock valued at $21,438,000 after acquiring an additional 17,891 shares during the last quarter. Finally, iSAM Funds UK Ltd raised its holdings in Boston Scientific by 144.2% during the third quarter. iSAM Funds UK Ltd now owns 21,966 shares of the medical equipment provider's stock worth $1,841,000 after acquiring an additional 12,972 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Analyst Upgrades and Downgrades

BSX has been the topic of several recent analyst reports. BTIG Research boosted their price target on Boston Scientific from $84.00 to $93.00 and gave the stock a "buy" rating in a research report on Monday, October 14th. Needham & Company LLC restated a "hold" rating on shares of Boston Scientific in a report on Wednesday, November 27th. Morgan Stanley increased their price target on shares of Boston Scientific from $92.00 to $100.00 and gave the company an "overweight" rating in a research note on Thursday, October 24th. Barclays boosted their price objective on shares of Boston Scientific from $78.00 to $86.00 and gave the stock an "overweight" rating in a research note on Thursday, August 22nd. Finally, Bank of America raised their target price on shares of Boston Scientific from $90.00 to $100.00 and gave the company a "buy" rating in a research note on Tuesday, October 22nd. Four equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $93.52.

Boston Scientific Price Performance

Shares of BSX stock traded down $1.26 during trading on Monday, hitting $88.81. The company had a trading volume of 2,063,032 shares, compared to its average volume of 5,995,840. The firm has a market capitalization of $130.89 billion, a P/E ratio of 73.92, a price-to-earnings-growth ratio of 2.65 and a beta of 0.80. Boston Scientific Co. has a one year low of $54.86 and a one year high of $91.93. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48. The stock's 50-day moving average price is $87.40 and its 200 day moving average price is $81.34.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, beating analysts' consensus estimates of $0.59 by $0.04. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The firm had revenue of $4.21 billion during the quarter, compared to the consensus estimate of $4.04 billion. During the same period in the prior year, the company posted $0.50 EPS. The company's revenue was up 19.3% compared to the same quarter last year. Equities analysts expect that Boston Scientific Co. will post 2.46 EPS for the current fiscal year.

Insider Buying and Selling

In other Boston Scientific news, Director Edward J. Ludwig sold 4,877 shares of the company's stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $91.63, for a total transaction of $446,879.51. Following the completion of the sale, the director now directly owns 39,398 shares in the company, valued at $3,610,038.74. This represents a 11.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Michael F. Mahoney sold 162,777 shares of Boston Scientific stock in a transaction on Monday, October 7th. The shares were sold at an average price of $84.63, for a total value of $13,775,817.51. Following the completion of the transaction, the chief executive officer now owns 1,572,096 shares in the company, valued at approximately $133,046,484.48. The trade was a 9.38 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 328,157 shares of company stock valued at $27,957,676 over the last quarter. 0.50% of the stock is owned by company insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.